News

A 53-year-old woman is complaining of this somewhat tender rash on her legs and feet that has been present for many months now.

A 48 year old man presents with a 2 year history of painful, disseminated, tender nodules covering his scalp. Many lesions are inflammatory with purulent discharge, and alopecia is noted over nodules. The patient reports clinical worsening after mental and physical stress. He has been treated with oral antibiotics, such as clindamycin hydrochloride and erythromycin, with poor response.

Some patients respond more rapidly to immune therapies like ipilimumab, and clinicians have observed delayed toxicities with prolonged use of checkpoint inhibitors; effective treatments for subtypes of melanoma, such as uveal melanoma, have not yet emerged.

New and advancing forms of technology could improve the detection and treatment of melanoma.

Cosmetic products are an interesting category because the cosmetics industry is self-regulated. This is in direct contrast to drugs that are carefully regulated by the FDA.

The signs and symptoms of some dermatologic and rheumatologic diseases sometimes overlap, and a better understanding of their associations and subsequent clinical and laboratory evaluations can help in optimizing the treatment and management of this patient population.

Scleroderma skin ulcers are challenging to manage and can be approached with a variety of therapies and treatments.

Even customer service, as vital to patients as it is, does not stand alone to create a stellar impression on patients. Your practice must excel in providing an intentional patient experience beyond the exam room.

When the tried-and-true mainstream acne treatments fail, it helps to use newer or lesser-known options. Learn more

BB creams came to the US from the Orient where they have been the rage for the past 3 years.

These are Dr. H.L. Greenberg’s top tips for treating (and preventing) acne.

Dr. Joel Schlessinger outlines the benefits for practices and patients alike for carrying certain product lines (and not others) in the office.

Why should dermatologists worry about psychological assessment tools in their practice? Pamela Schell Werschler, Psy.D., MSN, ARNP, DNC, answers.

Despite the variety of measurement points for the midface, Dr. Morris E. Hartstein says the Phi point is fixed and does not change with age.

Dr. Neal Bhatia shares his perspective on Actinic Keratosis from his Controversies session at the 23rd World Congress for Dermatology: pros and cons on routine eradication, trending populations, and modalities of treatment. learn more.

Many dermatologists may have wondered, however, why patients who use noncomedogenic products still develop acne.

Tina Alster, M.D., founding director of the Washington Institute of Dermatologic Laser Surgery in Washington, D.C. and clinical professor of dermatology at Georgetown University, talked with Dermatology Times’ Pamela Kreigh about the most important developments in laser scar revision and rejuvenation. Learn more

Fredric S. Brandt, M.D., one of cosmetic dermatology’s most celebrated, accomplished and recognized physicians, died April 5, 2015. His colleagues, still reeling from the loss, remember the legacy and brilliance of the man who came to be known as “The Baron of Botox.”

Probiotics, which are helpful bacteria that protect the body from harmful bacteria, are literally everywhere. In light of increasing antibiotic resistance due to over- and misuse, coupled with patients’ preferences for more holistic, natural approaches to healing, are we entering an era of anti-antibiotics and pro-probiotics?

The differential approach to diagnosis was first suggested a century ago by a pioneering German psychiatrist, Emil Kraeplin, but contributions to the evolution of the differential diagnosis (Ddx) have been made by countless outstanding physician-scientist-educators. Investing the time in direct communication with colleagues, rather than waging chart wars, is usually a very worthwhile win-win-win for clinicians, patients and colleagues.

Researchers assess the impact of facial erythema on the subconscious perceptions and initial reactions of others and how these affect their resulting attitudes.

Pediatric dermatology is a rewarding area of special interest for dermatologists. Overlapping conditions, the need for extra-gentle skin care, patient compliance, and medication adherence all present unique challenges for pediatric dermatologists. In part one of our discussion, Kelly Cordoro, M.D., associate professor of dermatology and pediatrics at the University of California in San Francisco, discusses differentiating diseases and treatment recommendations with Dermatology Times editorial advisor, Elaine Siegfried, M.D.

Researchers conducting a first-of-its-kind study combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug report the dual treatments are safe and produce a clinical response in metastatic melanoma patients. Learn more

Two days after it reported that the Food and Drug Administration had denied accelerated approval to Amgen experimental melanoma drug talimogene laherparepvec (T-Vec), Reuters reported that an FDA advisory panel voted to approve the drug for marketing. Get details

A doctor who prescribed oral retinoids to an acne patient is sued by the patient's family after the patient commits suicide. The doctor's career, practice, reputation and everything he holds dear are at risk simply because he tried to be a good doctor. Should he try to defend himself? Will he lose the case at trial?

It is sometimes challenging to pick a facial cleanser for acne patients because skin irritation and dryness can be magnified by improper cleansing techniques.

Dermatology practices are attracting private equity buyers who have the potential to swoop in and make problems like heavy debt vanish. But there are important considerations to take into account before signing away full ownership.

Initial improvements in difficult-to-treat forms of psoriasis persisted for a year with the phosphodiesterase 4 (PDE4) inhibitor apremilast (Otezla, Celgene Corp.), according to data from two recent trials. Learn more.

At a recent meeting, the Food and Drug Administration Dermatologic and Ophthalmic Drugs Advisory Committee supported early clinical development of systemic products for pediatric patients with atopic dermatitis that has been inadequately responsive to topical therapies.

A Phase 2 study of intralesional rose bengal disodium 10% (PV-10, Provectus Biopharmaceuticals) for refractory cutaneous melanoma had promising results and suggested induction of a systemic immune response that was confirmed in a separate pilot trial. Phase 3 launched in March 2015.